Senators Testify in Investigation That FDA Pulled Reviewer off Avandia
According to a Reuters article dated 7.24.07, a senior Food and Drug
Administration scientist has told congress in an investigation that the FDA
removed him or her from work on GlaxoSmithKline Plc's drug Avandia after voicing
concerns about the safety of the diabetes pill.
The FDA medical officer,
who has remained anonymous, was at one time the primary reviewer for Avandia,
according to a letter sent to the FDA by Senate Finance Committee Chairman Max
Baucus, a Democrat, and Sen. Charles Grassley, the panel's top
Republican.
The scientist has believed since 2005 that there was enough
evidence for a strong black box warning on Avandia about a risk of congestive
heart failure.
The FDA reviewer was told to stop participating in the
review of potential cardiovascular safety problems associated with
Avandia.
If you or a loved one has suffered cardiac complications after
ingesting Avandia, you deserve the guidance of a knowledgeable drug attorney.
Get a free case review by filling out the form below.
see also:
Second Black Box?
FDA: Black Box Warning Label Decision Pending on Avandia Diabetes DrugFDA to Announce Decision on Black Box for Avandia Soon--Lawsuit Info
Avandia Panel, 7.25.07
Academic Panel of Scientists to Meet With FDA Regarding Avandia RisksScientific Panel to Advise FDA on Avandia Heart Attack Risk
News & Warnings
Avandia Breaking News: Glaxo Warned in 2001 about Misleading MarketingBloomberg News: FDA Warned Glaxo about Avandia Marketing in 2001


